Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
The Russian government plans to approve the beginning of sales of drugs in convenience retail stores this year – in a move to make drugs more affordable to the local population, due to the reduction of prices for them, according to some senior officials of the Russian Ministry of Health and senior local experts in the field of pharmaceutics. 24 April 2019
Pharmaceutical
Professional investors are a fascinating group of individuals, enjoying an incredibly direct link between results and reward, so a lot can be learned from understanding how they focus effort, writes Brian McGee, partner at Novasecta, in an Expert View piece. 18 April 2019
Biotechnology
Biotech major Amgen on April 9 announced it had received US Food and Drug Administration approval for its osteoporosis treatment Evenity (romosozumab), nearly three months after the Japan approval. 17 April 2019
Pharmaceutical
Canada-based Canopy Growth is the world’s largest cannabis company, by market cap, and it aspires to be a world leader in developing the drug as a medicine. 17 April 2019
Pharmaceutical
The Pharmaceutical Price Regulation Scheme (PPRS) is dead; long live the Voluntary Scheme for Branded Medicines Pricing and Access (Voluntary Scheme)! 16 April 2019
Pharmaceutical
Global vaccines producers are losing their positions in the Russian market, due to the ever growing competition with local producers, which receive support from the state, according to recent statements of producers, reports The Pharma Letter’s local correspondent. 16 April 2019
Pharmaceutical
Japan’s largest drugmaker Takeda has officially launched the production of Advate (octocog alfa) - a drug for the treatment of patients with hemophilia A - at the facilities of its Russian partner, the Moscow-based Biocad plant. 16 April 2019
Pharmaceutical
Representatives from pharmacy benefit managers (PBMs) were the latest to be grilled by lawmakers in Washington DC on Tuesday. 10 April 2019
Pharmaceutical
Pharma needs to pay closer attention to ensuring the integrity of its third-party relationships, writes Kathy Johnson, vice president life sciences, LexisNexis Risk Solutions Health Care, in an Expert View piece. 9 April 2019
Generics
The Russian government plans to support the development of the domestic production of active pharmaceutical ingredients (APIs) by the provision of subsidies for their exports, according to Denis Manturov, an official spokesman of the Russian Minister of Industry and Trade, reports The Pharma Letter’s local correspondent. 9 April 2019
Pharmaceutical
The Russian Parliament has announced plans to limit the maximum share of pharmaceutical distributors and pharmacies in the domestic market and to oblige the latter to allocate up to 50% of their sale ranges for domestic drugs. 8 April 2019
Biotechnology
Chinese biotechs will seek more cross-border licensing deals in the coming years, especially for early-stage assets, said speakers at the annual China Healthcare Investment Conference (CHIC) held in late March in Shanghai. 8 April 2019
Pharmaceutical
A major fillip has been provided by the Indian government for new drugs approved for use in the EU, UK, Australia, Japan and the USA. Newly-minted clinical trial rules in India state drugs that have been approved in these countries no longer require trials in India, reports The Pharma Letter’s India correspondent. 5 April 2019
Pharmaceutical
An Expert View on a growing trend among drug developers from Rik Van Mol, vice president of R&D strategy, Europe, Veeva Systems. 4 April 2019
Pharmaceutical
The year-long US-China tension demands a fairer Chinese market access for global companies, and it might benefit China’s drug innovation, said speakers at the annual China Healthcare Investment Conference (CHIC) event held in Shanghai on March 27. 4 April 2019
Pharmaceutical
The immediate response of the pharmaceutical industry to the resignation of US Food and Drug Administration Commissioner Dr Scott Gottlieb on March 5, 2019, was one of shock. 3 April 2019
Pharmaceutical
More and more global drugmakers operating in Russia are considering suspension sales of at least part of their new range in the local market in the coming years, due to new rules on price regulation that were recently approved by the Russian Ministry of Health and which will take effect in 2020, according to recent statements of producers. 2 April 2019
Pharmaceutical
Russian Venture Company (RVC), a state-operated high-tech company specializing on the implementation of projects in the field of pharmaceuticals, has announced plans to invest more than $10 million in the development of a new device and a drug for the treatment of tuberculosis and cancer, reports The Pharma Letter’s local correspondent. 1 April 2019
Pharmaceutical
April is Fabry Disease Awareness Month and an opportunity to take a closer look at this rare inherited disease. Historically, the prevalence of Fabry disease was thought to be between one in 40,000 and one in 117,000. Newborn screening, performed in several countries, has shown that the prevalence is closer to one in 1,368 to one in 8,882.1 Dr Nicola Davies provides a summary of the condition, discusses treatment challenges, and highlights what pharma is doing to progress treatment within this therapeutic area. 1 April 2019
Biotechnology
Chinese biologics contract manufacturing organization (CMO) WuXi Biologics will continue to invest in capacity expansion in the USA and European Union to speed up its business growth, said the firm’s chief executive Chris Chen at a media conference held in Shanghai this month, reports The Pharma Letter’s local correspondent Wang Fangqing. 29 March 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze